Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

OBE2109 reduced menstrual bleeding and uterine volume in uterine fibroids (no add back) KLH1202 TRIAL: % OF DAYS WITH BLEEDING DURING 12-WEEK    TREATMENT PERIOD KLH1202 TRIAL: TIME TO NO BLEEDING FOR UTERINE    FIBROIDS PATIENTS KLH1202 TRIAL: CHANGE IN UTERINE VOLUME OVER TIME 50.0 (%) 40.0 Bleeding 30.0 with 28.98 Days 24.18 of 20.0 13.63 * Percentage 10.0 7.99 0.0 Placebo OBE2109 50 mg OBE2109 100 mg OBE2109 200mg p < 0.01 * Two sample t-test (vs Placebo) 100 90 80 (%) 70 estimate 60 Meier 50 40 an -Kapl 30 20 10 0 0 28 56 84 112 Time (Days) OBE2109 50 mg OBE2109 100 mg OBE2109 200 mg Placebo Censor 100 Mean±SEM OBE2109 50 mg OBE2109 100 mg OBE2109 200 mg Placebo volume 50 uterine 0 in ** * ** *** *** ** ** Percentage *** -50 *** Δ *** p < 0.05 * p < 0.01 ** p < 0.001 *** vs Placebo -100 Pretreatment Week 1 Week 4 Week 8 Week 12 Post-treatment (Week 4) Time (Weeks)